12:00 AM
Aug 24, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AG013: Phase Ib started

ActoGeniX began a single-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial to evaluate topical AG013 given 1, 3 or 6 times...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >